Troubled Biotechs Revisited: Peregrine Placing All Of Its Chips On Bavituximab
This article was originally published in The Pink Sheet Daily
Executive Summary
The story doesn’t end once a company is profiled in our periodic “troubled biotechs” roundups – here we check back in on three firms.